Research programme: KRAS inhibitors - Centre for Drug Design and Discovery
Latest Information Update: 09 May 2024
At a glance
- Originator Centre for Drug Design and Discovery
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 24 Apr 2024 Research programme: KRAS inhibitors - Centre for Drug Design and Discovery is available for licensing as of 24 Apr 2024. https://www.cd3.be/
- 24 Apr 2024 Early research in Solid tumours in Belgium (unspecified route) (Centre for Drug Design and Discovery pipeline, April 2024)